drug · small molecule
levodopa
Marketedupdated 5mo agoby PureIMS BV🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugINBRIJA31 co-mentions · 8 sources
- tagApproval22 co-mentions · 6 sources
- druglevodopa CR21 co-mentions · 8 sources
- drugSINEMET CR12 co-mentions · 3 sources
- drugentacapone10 co-mentions · 2 sources
- tagRecall3 co-mentions · 1 sources
- companyRising Pharma Holdings Inc3 co-mentions · 1 sources
- drug(carbidopa + levodopa)1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for parkinson disease and injury and 22 investigational indications.
indications
investigational
Parkinson's Disease
targets
D(3) dopamine receptor
all catalysts(5)
approval · 5
Dec 21, 2018
approval
INBRIJA (LEVODOPA) — FDA approval
levodopa
→
Aug 29, 2019
approval
INBRIJA (LEVODOPA) — FDA approval
levodopa
→
Aug 31, 2020
approval
INBRIJA (LEVODOPA) — FDA approval
levodopa
→
Aug 31, 2020
approval
INBRIJA (LEVODOPA) — FDA approval
levodopa
→
Mar 31, 2026
approval
INBRIJA (LEVODOPA) — FDA approval
levodopa
→
Trials studying levodopa
- —Real-world Patient Experiences With Inbrija®
- phase3A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
- phase1A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants
- phase1A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA®
- —Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease
- phase2Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations
- phase1A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
- phase2A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 3, 2029
~2.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Oct 21, 2033method-of-use (U-2484)US 12458615
- Nov 16, 2032formulationUS 8545878
- Nov 16, 2032formulationUS 8685442
- Nov 16, 2032formulationUS 8945612
- Nov 16, 2032formulationUS 9393210
- Feb 3, 2029method-of-use (U-2484)US RE437112.3y
News(4)
- AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeoverIn the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.biospace · 2d ago
- Reeling from past failures, Parkinson's pipeline enters 'era of diversification'While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson's dise…biospace · 22d ago
- BioVie shares halve on murky Parkinson’s disease readoutBioVie’s stock fell by nearly 50% as the biotech claimed victory in a mid-stage Parkinson’s disease trial using an alternative endpoint to the primary clinical goal.biospace · 1mo ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that